Abstract
Bacteriophages can be used effectively to cure bacterial infections. They are known to be active against bacteria but inactive against eukaryotic cells. Nevertheless, novel observations suggest that phages are not neutral for higher organisms. They can affect physiological and immunological processes which may be crucial to their expected positive effects in therapies. Bacteriophages are a very differentiated group of viruses and at least some of them can influence cancer processes. Phages may also affect the immunological system. In general, they activate the immunological response, for example cytokine secretion. They can also switch the tumor microenvironment to one advantageous for anticancer treatment. On the other hand, bacteriophages are used as a platform for foreign peptides that may induce anticancer effects. As bacterial debris can interfere with bacteriophage activity, phage purification is significant for the final effect of a phage preparation. In this review, results of the influence of bacteriophages on cancer processes are presented which have implications for the perspective application of phage therapy in patients with cancer and the general understanding of the role of bacteriophages in the human organism.
Similar content being viewed by others
Abbreviations
- BM-DCs:
-
Bone marrow-derived dendritic cells
- DCs:
-
Dendritic cells
- IFN:
-
Interferon
- IL:
-
Interleukin
- LPS:
-
Lipopolysaccharides
- MAGE:
-
Melanoma-associated antigens
- MMPs:
-
Metalloproteinase
- scFv:
-
Single-chain Fv
- sLeX:
-
Sialyl Lewis X protein
- TAMs:
-
Tumor-associated macrophages
- TNF:
-
Tumor necrosis factor
- VEGF:
-
Vascular endothelial growth factor
References
Arap W, Pasqualini R (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377–380
Bar H, Yacoby I, Benhar I (2008) Killing cancer cells by targeted drug-carrying phage nanomedicines. BMC Biotechnol 8:37
Binetruy-Tournaire R, Demangel C (2000) Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 19:1525–1533
Bloch H (1940) Experimental investigation on the relationships between bacteriophages and malignant tumors. Arch Virol 1:481–496 (in German)
Boratyński J, Syper D, Weber-Dabrowska B, Łusiak-Szelachowska M, Poźniak G, Górski A (2004) Preparation of endotoxin-free bacteriophages. Cell Mol Biol Lett 9:253–259
Borysowski J, Górski A (2004) Phage display technology and its application to experimental oncological therapy (in Polish). Postepy Hig Med Dosw 58:100–107
Dabrowska K, Opolski A, Wietrzyk J, Switala-Jelen K, Boratynski J, Nasulewicz A, Lipinska L, Chybicka A, Kujawa M, Zabel M, Dolinska-Krajewska B, Piasecki E, Weber-Dabrowska B, Rybka J, Salwa J, Wojdat E, Nowaczyk M, Gorski A (2004a) Antitumour activity of bacteriophages in murine experimental cancer models caused possibly by inhibition of β3 integrin signaling pathway. Acta Virol 48:241–248
Dabrowska K, Opolski A, Wietrzyk J, Switala-Jelen K, Godlewska J, Boratynski J, Syper D, Weber-Dabrowska B, Gorski A (2004b) Anticancer activity of bacteriophage T4 and its mutant HAP1 in mouse experimental tumour models. Anticancer Res 24:3991–3995
Dabrowska K, Switała-Jelen K, Opolski A, Weber-Dabrowska B, Gorski A (2005) Bacteriophage penetration in vertebrates. J Appl Microbiol 98:7–13
Dąbrowska K, Świtała-Jeleń K, Opolski A, Górski A (2006) Possible association between phages, Hoc protein, and the immune system. Arch Virol 151:209–215
Dąbrowska K, Zembala M, Boratyński J, Świtała-Jeleń K, Wietrzyk J, Opolski A, Szczaurska K, Kujawa M, Godlewska J, Górski A (2007) Hoc protein regulates The biological effects of T4 phage in mammals. Arch Microbiol 6:489–498
Dąbrowska K, Skaradziński G, Jończyk P, Kurzępa A, Wietrzyk J, Owczarek B, Zaczek M, Świtała-Jeleń K, Boratyński J, Poźniak G, Maciejewska M, Górski A (2009) The effect of bacteriophages T4 and HAP1 on in vitro melanoma migration. BMC Microbiol 9:13
Di Giovine M, Salone B, Martina Y, Amati V, Zambruno G, Cundari E, Failla CM, Saggio I (2001) Binding properties, cell delivery, and gene transfer of adenoviral penton base displaying bacteriophage. Virology 282:102–112
Eriksson F, Culp WD, Massey R, Egevad L, Garland D, Persson MAA, Pisa P (2007) Tumor specific phage particles promote tumor regression in a mouse melanoma model. Cancer Immunol Immunother 56:677–687
Eriksson F, Tsagozis P, Lundeberg K, Parsa R, Mangsbo SM, Persson MAA, Harris RA, Pisa P (2009) Tumor-specific bacteriophages induce tumor destruction through activation of tumor-associated macrophages. J Immunol 182:3105–3111
Fogelman I, Davey V, Ochs HD, Elashoff M, Feinberg MB, Mican J, Siegel JP, Sneller M, Lane HC (2000) Evaluation of CD4+ T cell function in vivo in HIV-infected patients as measured by bacteriophage phiX174 immunization. J Infect Dis 182:435–441
Fokine A, Chipman PR, Leiman PG, Mesyanzhinov VV, Rao VB, Rossmann MG (2004) Molecular architecture of the prolate head of bacteriophage T4. Proc Natl Acad Sci U S A 101:6003–6008
Fukuda MN, Ohyama C (2000) A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer Res 60:450–456
Gorski A, Weber-Dabrowska B (2005) The potential role of endogenous bacteriophages in controlling invading pathogens. Cell Mol Life Sci 62:511–519
Gorski A, Dabrowska K, Switala-Jelen K, Nowaczyk M, Weber-Dabrowska B, Boratynski J, Wietrzyk J, Opolski A (2003) New insights into the possible role of bacteriophages in host defence and disease. Med Immunol 2:2
Gorski A, Borysowski J, Miedzybrodzki R, Weber-Dabrowska B (2007) Bacteriophages in medicine. In: Mc Grath S (ed) Bacteriophage genetics and molecular biology. Caister Academic Press, Norfolk, p 125
Górski A, Wazna E, Weber-Dabrowska B, Dabrowska K, Switała-Jeleń K, Miedzybrodzki R (2006) Bacteriophage translocation. FEMS Immunol Med Microbiol 46:313–319
Hetian L, Ping A (2002) A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J Biol Chem 277:43137–43142
Kantoch M, Mordarski M (1958) Binding of bacterial viruses by cancer cells in vitro. Postepy Hig Med Dosw 12:191–192
Kelly E, Russell SJ (2007) History of oncolytic viruses: genesis to genetic engineering. Mol Ther 15:651–659
Koivunen E, Arap W (1999) Tumor targeting with a selective gelatinase inhibitor. Nat Biotechmol 17:768–774
Kucharewicz-Krukowska A, Slopek S (1987) Immunogenic effect of bacteriophage in patients subjected to phage therapy. Arch Immunol Ther Exp (Warsz.) 35:553–561
Kutter E (1997) Phage therapy: bacteriophages as antibiotics, http://www.evergreen.edu/phage/phagetherapy/phagetherapy.html
Leiman PG, Kanamaru S, Mesyanzhinov VV, Arisaka F, Rossmann MG (2003) Structure and morphogenesis of bacteriophage T4. Cell Mol Life Sci 60:2356–2370
Li XB, Schluesener HJ, Xu SQ (2006) Molecular addresses of tumors: selection by in vivo phage display. Arch Immunol Ther Exp (Warsz) 54(3):177–181
Lorch A (1999) Bacteriophages: an alternative to antibiotics? Biotechnol Dev Monit 39:14–17
Międzybrodzki R, Fortuna W, Weber-Dąbrowska B, Górski A (2009) A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin Exp Med. doi:10.1007/s10238-009-0044-2
Newton J, Deutscher SL (2008) Phage peptide display. Handb Exp Pharmacol 185(Pt 2):145–163
Nilsson F, Kosmehl H (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin mediates the infarction of solid tumors in mice. Cancer Res 61:711–716
Pajtasz-Piasecka E, Rossowska J, Duś D, Weber-Dabrowska B, Zablocka A, Gorski A (2008) Bacteriophages support anti-tumor response initiated by DC-based vaccine against murine transplantable colon carcinoma. Immunol Lett 116:24–32
Przerwa A, Zimecki M, Switała-Jeleń K, Dabrowska K, Krawczyk E, Łuczak M, Weber-Dabrowska B, Syper D, Miedzybrodzki R, Górski A (2006) Effects of bacteriophages on free radical production and phagocytic functions. Med Microbiol Immunol 195:143–150
Qiu J, Luo P, Wasmund K, Steplewski Z, Kieber-Emmons T (1999) Towards the development of peptide mimotopes of carbohydrate antigens as cancer vaccines. Hybridoma 18(1):103–112
Ribas A, Butterfield LH, Economou JS (2000) Genetic immunotherapy for cancer. Oncologist 5:87–98
Shearer WT, Lugg DJ, Rosenblatt HM, Nickoll PM, Sharp RM, Reuben JM, Ochs HD (2001) Antibody responses to bacteriophage phiX174 in human subjects exposed to the antarctic wind-over model of spaceflight. J Allergy Clin Immunol 107:19–20
Sinkovics JG, Horvath JC (2008) Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp (Warsz) 56(Suppl 1):3s–59s
Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315–1316
Szczaurska-Nowak K (2009) Badanie mechanizmu działania przeciwnowotworowego preparatu fagowego BP T4 u myszy obarczonych przeszczepialnym czerniakiem B16 (In Polish). Dissertation, Polish Academy of Science, Institute of Immunology and Experimental Therapy, Wroclaw, Poland
Tallant C, Marrero A, Gomis-Rüth FX (2009) Matrix metalloproteinases. Fold and function of their catalytic domains. Biochim Biophys Acta. doi:10.1016/j.bbamcr.2009.04.003
Uchiyama F, Tanaka Y, Minari Y, Tokui N (2005) Designing scaffolds of peptides for phages display libraries. J Biosci Bioeng 99(5):448–456
Vitaliti A, Wittmer M (2002) Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular growth factor. Cancer Res 60:4311–4314
Weber-Dabrowska B, Mulczyk M, Gorski A (2001) Therapy of infections in cancer patients with bacteriophages. Clin Appl Immunol Rev 1:131
Woo Y, Adusumilli PS, Fong Y (2006) Advances in oncolytic viral therapy. Curr Opin Investig Drugs 7:549–559
World Health Organization (2002) WHO health topics, antimicrobial resistance (fact sheet 194, Jan 2002). http://www.who.int/topics/en/
World Health Organization (2005) World alliance for patient safety “WHO Guidelines on hand hygiene in health care (advanced draft): a summary”. http://www.who.int/patientsafety/events/05/HH_en.pdf
Acknowledgments
This work was supported by EU Structural Funds (Operational Program Innovative Economy “Optimization of characteristics and preparing of bacteriophage preparations for therapeutic purposes”) and the Polish Ministry of Science (grant no. N N401 1305 33 and no. N N401 417236).
Conflict of interest statement
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicated by Erko Stackebrandt.
Rights and permissions
About this article
Cite this article
Budynek, P., Dąbrowska, K., Skaradziński, G. et al. Bacteriophages and cancer. Arch Microbiol 192, 315–320 (2010). https://doi.org/10.1007/s00203-010-0559-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00203-010-0559-7